Gene Reports 25 (2021) 101392 Available online 12 October 2021 2452-0144/© 2021 Published by Elsevier Inc. MiR-1307: A comprehensive review of its role in various cancer Shirin Saberianpour a , Leila Abkhooie b, * a Vascular and Endovascular Surgery Research Center, Mashhad University of Medical Sciences, Mashhad, Iran b Department of Medical Biotechnology, Faculty of Medicine, Lorestan University of Medical Sciences, Khorramabad, Iran A R T I C L E INFO Keywords: miRNAs miR-1307 Cancer ABSTRACT Various investigations have indicated that miRNAs play a critical role in a wide range of biological functions, like cell differentiation, metabolism of energy, proliferation, and apoptosis. MiRNAs are signifcantly dysregulated in cancerous cells and malignancies. It has been demonstrated miRNA has two functions in cancer progression: it can stimulate carcinogenesis by blocking tumor suppressors or it functions as a tumor suppressor by helping down-regulation of oncogenes. MiR-1307, which has been recently discovered as a cancer-associated miRNA, is considered a risk factor for the development of metastatic types of cancers. MiR-1307 levels in serum are increased in breast cancer and can be used to diagnose the disease early. Data show that miR-1307-3p is an oncogenic miRNA with a signifcant contributory role in the development and progression of the thorough targeting SMYD4. Furthermore, this miRNA helps to the proliferation of cancer cells include of breast, ovarian, colorectal, lung, and so on. MiR-1307 overexpress in gastric cancer cell lines and its interaction with DAB2 protein lead to promote the behavior of tumoral cells such as proliferation and migratory and metastasis. In hepatocellular carcinoma (HCC) miR-1307-3p promotes HCC proliferation, invasion, and advancement by reducing DAB2 protein. In ovarian cancer, miR-1307 infuence the cell cycle of tumoral cells and decline the response to chemotherapy drugs in ovarian cancer by regulation of the CIC (capicua transcriptional repressor) gene. Another mechanism for miR-1307-3p was seen in colon adenocarcinoma miR-1307-3p can be bind to the 3 ′ -untranslated area of TUSC5 and control progression and metastasis of colon adenocarcinoma cells. MiR-1307- 5p can binds to TRAF3 and stimulates the NF-B/MAPK pathway to enhance the proliferation of lung tumor. In this review study, we try to recapitulate the role of miR-1307 in the process of pathogenesis and treatment of various cancers according to recently published studies. 1. Introduction MicroRNAs (miRNAs), as a group of small non-coding RNAs are involved in regulating a variety of biological events like differentiation, proliferation, apoptosis, physiology, metabolism, and diseases (Abkhooie et al., 2021; O’Brien et al., 2018; He et al., 2019; Wang et al., 2018). It has been shown that miRNAs are signifcantly dysregulated in cancerous cells and malignancies (Chen et al., 2019a; Peng and Croce, 2016; Si et al., 2019; Daoud et al., 2019). Abnormalities of chromosome changes in the regulation of transcription, epigenetic modifcations, and defciencies in the biogenesis machinery of miRNAs are considered the underlying mechanisms (Assis et al., 2021; Abkhooie et al., 2021; Mo- rales et al., 2017; Tomasetti et al., 2019). Comparing malignant cells to the normal ones revealed that abnormal expression of miRNA is frequently associated with changes in genomic copy numbers of miRNAs and location of genes (translocation amplifcation or deletion). Lin-4 was the frst miRNA that was identifed in Caenorhabditis elegans (C. elegans) by Ambros et al. (Maatouk and Harfe, 2006). According to evidence collected, microRNAs are very infuential on formation of a tumor, progress and its treatment. About 50% of miRNAs are placed in friable spots concerned with tumor or genomic areas, which shows their great importance (Yang et al., 2017). MicroRNAs Abbreviations: miRNA, microRNA; B-CLL, B-cell chronic lymphocytic leukemia; TGF signaling, transforming growth factor signaling; RCC, renal cell carcinoma; TKI, tyrosine kinase inhibitors; SMYD4, SET and MYND domain contained 4; DAB2IP, DAB2 protein; HCC, hepatocellular carcinoma; SEC14L2, SEC14 Like Lipid Binding 2; ENG, Endoglin; MEIS2, Meis Homeobox 2; LATS1, Large Tumor Suppressor Kinase 1; CIC, capicua transcriptional repressor; Colon adenocarcinoma, COAD; TUSC5, Tumor suppressor candidate 5; PRRX1, Paired Related Homeobox 1; ISM1, Isthmin 1; TYMS, Thymidylate Synthetase; RFS, recurrence/relapse-free survival; NSCLC, Non-Small Cell Lung Cancer; TRAF3, TNF Receptor Associated Factor 3; NF-κB, nuclear factor-κB; MAPK, mitogen-activated protein kinase. * Corresponding author. E-mail address: lilaabkhooie@yahoo.com (L. Abkhooie). Contents lists available at ScienceDirect Gene Reports journal homepage: www.elsevier.com/locate/genrep https://doi.org/10.1016/j.genrep.2021.101392 Received 31 August 2021; Received in revised form 28 September 2021; Accepted 5 October 2021